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Sharon Elad,1 Itai Zeevi,1 Reuven Or,2 Igor B. Resnick,2 Lilian Dray,2 Michael Y. Shapira2The aim of this study was to validate the 2005-2006 National Institutes of Health (NIH) scale for patient’s
self-reporting and clinical manifestations of oral chronic graft-versus-host disease (cGVHD). Numerical
parameters of the NIH scale were analyzed for their construct validity (correlation of the NIH scale with
numerical rating scale [NRS] for pain) and internal consistency reliability (correlation between different
parameters of the same scale). Categoric parameters were analyzed by comparison between severity
subgroups defined by the oral manifestation (lichenoid/erythema/ulceration). Analysis included data of 75
evaluations. The total NIH score and the NRS for pain were found to be moderately correlated
(r5 0.449). Cronbach’s alpha reliability coefficient was .718. Strong correlations were found between the
total NIH score and both erythema and ulceration scores (r5 0.746 and r5 0.926, respectively). The dif-
ference between the 2 ‘‘severe’’ subgroups (ie, lichenoid and erythema/ulceration) was significant
(P5.025). The difference between the moderate-erythema/ulceration subgroup and the severe-lichenoid
subgroup was nonsignificant (total NIH score and NRS for pain: P5.276 and .291, respectively). The corre-
lation between the total NIH score and the NRS for pain is only moderate. The internal consistency reliability
analysis yielded good reliability, especially for erythema and ulceration. Analysis of categoric parameters
suggests that the NIH scale disproportionately differentiates between moderate-erythema/ulceration and
severe-lichenoid cGVHD.
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Chronic graft-versus-host disease (cGVHD) is
a major complication of allogeneic hematopoietic
stem cell transplantation (HSCT). GVHD is an
alloimmune inflammatory process, which results
from a donor-origin cellular response against host
tissue and occurs as acute GVHD (aGVHD) in
50%-70% and cGVHD in 30%-50% allogeneic trans-
plants (40%-80% of long-term survivors) [1]. Oral
involvement may be seen in up to 80% of patients1Department of Oral Medicine, Hebrew University,
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6/j.bbmt.2009.08.018affected by cGVHD, making these lesions an easily
observable sign for the presence of systemic disease [2].
Common areas of oral involvement include the
tongue, buccal mucosa, and labial mucosa [2,3]. In
oral cGVHD, oral lesions are often hyperkeratotic,
lichenoid, erythematous, ulcerative, and desquama-
tive. In some cases mucoceles may be present [2,3].
Scleroderma-like stiffness of the oral soft tissues can
limit mouth opening [4]. Painful mucosal lesions
may represent a significant impediment to nutritional
intake and to maintaining oral hygiene. cGVHD may
also be associated with progressive salivary gland dys-
function and hyposalivation [5,6].
The severity of cGVHD needs to be established
for the purposes of defining therapeutic needs and
for evaluating response to treatment. In addition, scor-
ing cGVHD severity will allow for standardized
descriptions of the oral condition, thus facilitating
communication between clinicians.
Several scales for assessing the severity of cGVHD
have been proposed and used for research purposes.
Some of them were based on scales for assessing
chemotherapy-induced oral mucositis, with adjust-
ments for typical manifestations of cGVHD [7-12].
Biol Blood Marrow Transplant 16:62-69, 2010 63Validation of the NIH Scale for cGVHDOf interest is a study that verified the relationship
between the oral changes as assessed by the National
Institutes of Health (NIH) oral cGVHD scale and
active cGVHD [12]. The NIH Consensus Project
guidelines for the evaluation of cGVHD were pub-
lished during the latter part of 2005 and early 2006
[13,14]. This new clinical scoring system measures
the extent and severity of cGVHD for various organs
and sites at any given time. However, the criteria
proposed in the NIH scale are admittedly arbitrary,
because they have never been validated for patients
with cGVHD. Therefore, it is unknown whether the
oral cGVHD severity score according to the new
NIH scale is actually correlated with the patient symp-
toms or with the type of oral manifestation of the
disease.
Our aim in this study is to validate the new NIH
scale in measuring the severity of oral cGVHD.METHODS
Study Design
This historically prospective study was performed
at the Oral Medicine Service of the Hadassah Univer-
sity Hospital, between July 2006 and February 2008,
with the approval of the hospital ethics committee
and in accordance with the Declaration of Helsinki.
Consecutive patients with a minimum of 3 months
postallogeneic HSCT and diagnosed as having
cGVHD were included. All enrolled patients were
evaluated according to the new NIH scale for
cGVHD, and their descriptions of their oral pain
were recorded. Patients with partial documentation
of the NIH score or score for pain were excluded. All
the demographic data of the enrollees, including age,
sex, and medical background, were retrieved from
medical records.NIH Scale
The NIH scale for the activity assessment of oral
cGVHD provides several scores [14]: a score that mea-
sures the severity of each type of oral manifestation
separately, a total score, and a severity grade. The of-
ficial table format of the scale appears on the Biology
of Blood and Marrow Transplantation Website: Ap-
pendix A at http://www.asbmt.org/GvHDForms.
It is briefly described below.
Type of oral manifestation
The individual scores of the 4 cGVHD manifesta-
tions are determined according to the following [14]:
(1) mucosal erythema (based on the color intensity
and relative size of the oral surface involved: 0—none,
1—mild erythema or moderate erythema\25%, 2—
moderate erythema.25% or severe erythema\25%);(2) lichen-type hyperkeratosis (percent of oral surface
involved: 0—none, 1—surface involved\25%, 2—sur-
face involved 25%-50%, 3—surface involved .50%);
(3) ulcerations (percent of oral surface involved: 0—
none, 3—surface involved\20%, 6—surface involved
.20%); and (4) presence of mucoceles (total number:
0—none, 15 1-5, 25 5-10, and 35.10).
Total score
The total score of the NIH scale is the sum of the
individual scores defined above. It ranges from 0 to 15,
with the higher scores indicating more severe involve-
ment.
Severity level
In addition to numerical scoring, the NIH scale
classifies the oral cGVHD status according to the
severity of the 4 oral cGVHD manifestations:
erythema, lichenoid, ulceration, and mucocele [14].
The severity of mucosal changes is categorized as
none, mild, moderate, and severe according to the scores
described above (see Type of oral manifestation). A score
of 1 for a lichenoid, erythema, and mucocele oral man-
ifestation is defined asmild. A score of 2 for a lichenoid,
erythema, and mucocele and/or a score of 3 for ulcer-
ation manifestation is defined as moderate. A score of 3
for a lichenoid, erythema, and mucocele and/or 6 for
ulceration manifestation is defined as severe.
Pain Score
The patients reported their oral status and pain
score on an 11-point numerical rating scale (NRS),
with 0 being no pain and 10 being worst imaginable
pain. The patients were asked to refer to their pain
level while eating. This scale has been used extensively,
and has been demonstrated to be a valid instrument for
the measurement of intensity of pain in other oral dis-
ease conditions [15-19].
Analysis of Numerical Parameters
Numerical parameters were analyzed for their
construct validity and internal consistency reliability
(Table 2, rows 1 and 2).
Construct validity
Construct validity is the degree to which a scale
correlates with a theoretic concept [15,20]. To assess
the construct validity of the NIH scale, we relied on
the recognized correlation between oral cGVHD
presentation and oral pain [2,11,14,21]. Therefore,
we assessed the construct validity by correlating the
NIH scale with oral pain levels. NRS is an accepted
scale used to describe the symptomatic level of an
oral condition [15-17,19,22], and it was correlated
with the following parameters of the NIH scale: total
score, lichenoid score, erythema score, ulceration
Table 1. Patients Characteristics
Total number
of visits
75
Patients (F:M ratio) 20 (7:13)
Age (years) (avg ± SD) 37 ± 18
Visits per patient (avg ± SD) 4 ± 3
Time since HSCT (months) (avg ± SD) 40 ± 36
Diagnosis
Leukemia 14
Lymphoma 3
Fanconi anemia 2
Multiple sclerosis 1
HSCT indicates hematopoietic stem cell; F, female; M, male; avg, average;
SD, standard deviation.
64 Biol Blood Marrow Transplant 16:62-69, 2010S. Elad et al.score, combined erythema plus ulceration score, and
mucocele score. The scores for each of the NIH scale’s
parameters were obtained from the entire group of
evaluations (Table 2, row 1; parameters compared
are marked with ‘‘1’’).
Internal consistency reliability
Internal consistency reliability was defined as the
correlation between different parameters of the same
scale [15,23]. It reflects how consistent 1 aspect of
the scale is relative to the total score or to other aspects
of the same scale. To assess the internal consistency re-
liability for the 4 selected parameters of the NIH scale
(erythema, lichenoid, ulceration, and mucocele) we
used Cronbach’s alpha reliability coefficient. Further-
more, each type of oral manifestation was correlated
with the total NIH score and with the scores of other
oral manifestations (eg, the lichenoid score was corre-
lated with the total NIH score, the erythema score, the
ulceration score, and the mucocele score) (Table 2,
row 2; the compared parameters aremarkedwith ‘‘1’’).Analysis of Categoric Parameters
Stratification according to the most dominant
component
The subgroups were defined according to the
dominant type of lesion as follows: (1) cases in which
the lichenoid component was the worst of all the
components, and (2) cases in which the erythematous
or ulceration components were the worst of all
the components. This stratification resulted in the
following comparisons: moderate-lichenoid versus
moderate-erythema/ulceration, severe-lichenoid versus
severe-erythema/ulceration, and moderate-erythema/
ulceration versus severe-lichenoid. This analysis was
repeated for 2 parameters, that is, the NIH total score
and the NRS for pain.Statistical Analysis
Correlation analyses for the numerical parameters
were performed using Pearson’s correlation and Cron-
bach’s alpha reliability coefficient. The list of correla-
tions appears in Table 2, rows 1 and 2. Because the
signs and symptoms of oral cGVHD are known to
fluctuate considerably over time, each patient visit
was considered a distinct unit, so the same individual
could account for multiple visits and evaluations. (Val-
idation of this approach is detailed in the Supplement.)
We describe correlations as ‘‘weak’’ or as having
‘‘no association’’ if they were between 0 and 0.29
(or 0 and 20.29), ‘‘moderate’’ if they were between
0.30 and 0.69 (or 20.30 and 20.69), and ‘‘strong’’ if
they were between 0.7 and 1 (or 20.7 and 21).The categoric parameters were compared using
the analysis of variance (ANOVA). The list of compar-
isons appears in Table 2, rows 3, and Table 3.
Differences were considered significant at a P-
value of\.05. The statistical analyses were performed
using SPSS for Windows, version 14.0 (SPSS Inc.,
Chicago, IL).RESULTS
Patient Characteristics
Seventy-five evaluations involving 20 patients were
performed using the NIH scale.
Table 1 lists the participants’ demographic data
and indication for HSCT. The systemic regimen
that these patients received was based on prednisone
1mg/kg/day. Patients failing this first line of treatment
were treated by calcineurin inhibitors, cyclosporine or
tacrolimus. The patients were optionally treated with
extra-corporal photopheresis, imuran, and penicilla-
mine. Supportive care included extensive infectious
prophylaxis and prophylaxis against noninfectious
side effects of the transplantation or the medications.
Topical treatment included corticosteroids (dexa-
methasone, budesonide, or triamcinolone acetonide),
antiseptics (chlorhexidine or nystatin), and supportive
care (various saliva substitutes). Some of the patients
had been on topical oral cGVHD management medi-
cations within approximately 3-4 weeks prior to being
evaluated for this study.
Analysis of Numerical Parameters of the NIH
Score
Construct validity
The total NIH score and the NRS for pain were
found to be moderately correlated (r5 0.449) (Table 2,
row1).Correlations between theNIHscores for each of
the 4 selected types of oral manifestations and the NRS
for pain are presented in Table 2, row 1. The erythema
and ulcerations scores were found to bemoderately cor-
related with the score for pain (r5 0.372 and r5 0.367,
respectively), whereas the lichenoid score and the NRS
for pain were weakly correlated (r5 0.278).
Table 2. Study Design: Analysis of Numerical
Analysis
Parameters Compared
Pearson*
NIH Scale
NRS for PainTotal Score
Type of Oral Manifestation
L E U E + U M r-value
1. Construct validity + + .449
+ + .278
+ + .372
+ + .367
+ + .400
+ + .063
2. Internal consistency reliability
Cronbach’s alpha5 0.718
1 + + .298
2 + + .746
3 + + .926
4 + + .954
5 + + .293
6 + + .122
7 + + .018
8 + + .049
9 + + .016
10 + + .606
11 + + .768
12 + + .053
13 + + .975
14 + + .172
15 + + .154
L indicates lichenoid; E, erythema; U, ulceration; M, mucocele; Mil, mild; Mod, moderate; Sev, severe; NRS, numerical rating scale.
*Pearson’s correlation.
Biol Blood Marrow Transplant 16:62-69, 2010 65Validation of the NIH Scale for cGVHDThe similar trends that had been observed for the
erythema and ulceration scores during the tests for
construct validity (preceding paragraph) suggest that
these 2 types of oral manifestations share a common
behavior pattern. Thus, it was decided to add a com-
bined parameter to the statistical evaluation, that of er-
ythema plus ulceration. The combined score and the
NRS for pain were moderately correlated as well
(r5 0.4).
No correlation was found between the mucocele
score and the NRS for pain (r5 0.063)
Internal consistency reliability
Cronbach’s alpha reliability coefficient was 0.718.
Regarding the interitem assessments (Table 2, rowTable 3. Analysis of the Evaluations per cGVHD Severity Level and
Major Component
(No. of evaluations [%])
NIH Score
(avg. ± SD)
cGVHD Severity
According to the
NIH Scale L E/U L E/U P-Value* L
Mild (n5 7) 3 (8.8%) 4† (9.7%) 1 2† ‡ 0
Moderate (n5 36) 12 (35.3%) 24 (58.5%) 3 ± 1 6 ± 1 <.001 3 ±
Severe (n5 32) 19 (55.8%) 13 (31.7%) 6 ± 2 10 ± 2 <.001 5 ±
cGVHD indicates chronic graft-versus-host disease; NRS, numerical rating sc
ulceration.
*ANOVA
†Erythema only.
‡Sample size too small for statistical analysis.2), the total NIH score correlated strongly with both
the erythema and ulceration scores (r5 0.746 and
r5 0.926, respectively) (Table 2, rows 2.2 and 2.3).
In contrast, the total NIH score correlated much
more weakly with both the lichenoid and mucocele
scores (r5 0.298 and r5 0.293, respectively).
Analysis of the correlations between the different
types of oral manifestations yielded a moderate corre-
lation coefficient for the erythema and the ulceration
scores (r5 0.606). There was no correlation between
the lichenoid/mucocele scores and the scores of other
types of oral manifestations (Table 2, rows 2.6, 2.7, 2.9,
2.12, and 2.14). The correlation coefficient for the
erythema and the ulceration scores was the strongest
among the interitem correlations, which ranged fromType of Oral cGVHD Manifestation
NRS for Pain
(avg. ± SD)
NIH Score
(avg. ± SD)
NRS for Pain
(avg. ± SD)
E/U P-Value* L E/U P-Value* L E/U P-Value*
2 ± 3† ‡
2 4 ± 3 .274 6 ± 1 0.276 4 ± 3 .291
4 8 ± 3 .025 6 ± 2 5 ± 4
ale; avg, average; SD, standard deviation; L, lichenoid; E/U, erythema or
66 Biol Blood Marrow Transplant 16:62-69, 2010S. Elad et al.0.016 to 0.606 (Table 2, rows 2.6, 2.7, 2.9, 2.10, 2.12,
and 2.14). The relatively strong correlation between
the erythema and ulceration scores (Table 2, row
2.10) is another support for the merge of these 2 types
of oral manifestations given their similar behavior
pattern.Analysis of Categoric Parameters
Stratification according to the most dominant
component
Having found that the oral manifestations of
erythema and ulceration were similar in nature to
one another and different from that of the lichenoid
type (see Construct validity and internal consistency reli-
ability), it was decided to combine the cases in which
either erythema or ulceration was the major compo-
nent in the total NIH score into a single subgroup
for the stratification analysis. Furthermore, based on
the very low correlation between the NRS for pain
and the mucocele score, on the fact that this cGVHD
manifestation was noted in only 16 evaluations of 6
patients, and on its having been scored as being mild
in all cases, the mucocele type was not included in
the stratification analysis. Consequently, subsequent
analyses continued independently for the lichenoid
and erythema/ulceration subgroups, and its results
are detailed below.
Twenty-four of the 41 ulcerative/erythematous
cases were graded as being ‘‘moderate’’ and 19 out of
the 34 lichenoid cases were graded as being ‘‘severe’’
(Table 3). Whereas the difference between the aver-
aged NIH score of the 2 subgroups of moderate sever-
ity (lichenoid versus erythema/ulceration) was
significant (P\ .001), the difference in the NRS for
pain for these 2 subgroups was not (P5 .274)
(Table 3).
The differences between both the averaged NIH
score and the NRS for pain for the 2 subgroups of
severe disease (lichenoid versus erythema/ulceration)
were significant (P\ .001 and P5 .025, respectively)
(Table 3).
Because the severe-lichenoid subgroup and the
moderate-erythema/ulceration subgroup had an
overlapping range of their NIH scores (ie, an NIH
score of 66 1), the NIH score and NRS for pain of
these 2 subgroups were compared (Table 3). The
statistical analysis revealed that there was no signifi-
cant difference between them for either the NIH score
(P5 .276) or the NRS for pain (P5 .291).DISCUSSION
The new NIH scale for cGVHD is an important
step in the development of clinical tools for the man-
agement of cGVHD patients. The goal was to developa scale that would simplify the assessments as much as
possible to facilitate their use by clinicians outside the
field of HSCT on the 1 hand, while ensuring that the
assessments should contain as much information as
possible to support research on the other. This scale
was based on a broad consensus of experts and on the
use of the best available data. It has not, however,
been validated until now.We designed this historically
prospective study to assess total NIH scores and the
components of the scale in a large collection of clinical
evaluations.
Our construct validity analysis sought agreement
between the new NIH scale and prior knowledge
about oral pain in cGVHD patients. The results of
that analysis showed a moderate correlation between
the NIH score and the NRS for pain with respect to
the total NIH score, the erythema score, the ulceration
score, and the combined score for erythema plus ulcer-
ation. These findings are supported by the studies of
Treister et al. and Chainani-Wu et al. [11,15,17],
which demonstrated that the presence of erythema
and ulcerations has a profound impact on the overall
symptoms of oral pain The NIH scale does specifically
weigh ulcerative changes, and reflects an increased im-
pact and severity of disease activity. Breakdown of the
epithelial barrier would be expected to be associated
with more pain. Erythema would be expected to be
somewhere between lichenoid changes and ulcerative
lesions relative to their impact on pain, especially
because erythema seems to be associated with varying
degrees of mucosal thinning (or atrophy). The weak
correlation coefficients between the NRS for pain
and the lichenoid/mucocele scores reveals an absence
of such correlations. Indeed, it is reported in the liter-
ature that lichenoid lesions are usually asymptomatic,
and, thus, are rarely associated with pain [9,11,17,24],
and that mucoceles are typically described as more of a
nuisance rather than being painful [3,11,25-27]. Be-
cause the mucocele component of the NIH oral
cGVHD scale was probably included as an element
of salivary involvement of cGVHD, correlation of
mucoceles may best be analyzed relative to complaints
of xerostomia.
The following conclusions are based on the
construct validity analysis:
1. Overall, the NIH scale is indicative of the sever-
ity of oral cGVHD as reflected by the pain level, how-
ever, up to a moderate level. The presence of erythema
and ulceration is specifically indicative of the severity
of oral cGVHD, more than are the lichenoid and mu-
cocele components. There are 2 possible explanations
for the moderate correlation between the total NIH
score and the NRS for pain. First, analgesics are
in commonuse in post-HSCTpatients because ofmul-
tiorgan complications, and their simultaneous use
may result in lower scores for oral pain [10]. Second,
according to the literature, both ulcers and erythema
Biol Blood Marrow Transplant 16:62-69, 2010 67Validation of the NIH Scale for cGVHDlocated on the tongue are associated with more pain
than when located on other oral surfaces [15], possibly
because of the friction of the tongue during function
and its large contact surface with foods. Our analysis
did not stratify data according to the mucosal surface
involved. Theoretically, 2 patients with the same type
of lesion but in different locations may have scored
their pain levels differently. Analysis of this speculation
is beyond the scope of this study. Therefore, it is possi-
ble that the location of the lesion was a confounding
factor that moderated the correlation between the total
NIH score and theNRS for pain. 2. Erythematous and
ulceration types of cGVHDmanifestations are compa-
rable and, for the purpose of the analysis in this study,
could be combined into 1 group. Indeed, the correla-
tion between the combined score of erythema plus
ulceration and the NRS for pain was higher than the
correlation between the scores of these 2 types of oral
manifestations and NRS for pain taken separately.
This finding is supported by the study of Chainani-
Wu et al. [15], who demonstrated that, for clinical
signs, erythema plus ulceration is a better measure
than erythema or ulceration alone. Furthermore, the
erythematous and ulceration types are different than
the lichenoid type, because the correlation between
the lichenoid score and the NRS for pain is weaker
relative to the correlations between the erythematous
and ulceration scores and the NRS for pain. This indi-
cates that the lichenoid type needs to be analyzed sep-
arately, a finding that is supported by previous studies
that confirmed that erythematous and ulceration types
are different from the lichenoid type in terms of
discomfort and pain [9,11,17,24].
The following conclusions are based on the inter-
nal consistency analysis:
1. Overall, the internal consistency analysis yields
good reliability. The internal consistency reliability
analysis tests the extent to which each of the compo-
nents of the NIH scale assesses oral cGVHD and
the extent to which they are consistent among
themselves. Cronbach’s alpha expresses the level
of this reliability, and a value of 0.7 is considered
as having good reliability [28,29]. The interitem
correlations analysis for the 4 parameters of the
NIH scale, however, showed strong correlations
in only 2 cases: between the total NIH score and
the erythema score, and between the total NIH
score and the ulceration score.
2. Erythematous and ulceration types of cGVHD
manifestations are comparable. The high reliability
of the erythematous and ulceration types streng-
thens the finding from the construct validity analysis
on their similarity. Likewise, the correlation be-
tween the combined score of erythema plus ulcera-
tion in the internal consistency reliability analysis
and the totalNIH score was higher than the correla-tion between the scores of these 2 types of oral man-
ifestations and the total NIH score taken separately.
Contrarily, the inter-item correlations analysis
showed no correlation between the scores of the
lichenoid/mucocele types and the scores of the other
types of oral manifestations.
To summarize, internal consistency reliability of
the NIH scale can be considered as being only partial:
it is reliable for the erythematous and ulceration types
but not for the lichenoid and mucocele types. A better
construct validity and internal consistency reliability
for the lichenoid type of oral manifestation can be
achieved if this component in the scale would have
a smaller fraction of the total NIH score (ie, a lower
score relative to the score for erythema).
The categoric parameters of the scale were ana-
lyzed in the second phase.
Each of the cGVHD severity levels, that is, mild,
moderate, and severe, was stratified according to the
type of oral manifestation.
Based on the observation of a large overlap in the
NIH score between moderate and severe cases, we as-
sessed the differentiation between various types of
oral manifestations of these 2 severity levels. The sta-
tistical analysis showed that the moderate-erythema/
ulceration subgroup and the severe-lichenoid sub-
group were not significantly different in pain and
NIH scores. The clinical meaning of these findings
is that there is a range of cGVHD types and severities
in which the NIH scale will not be able to differenti-
ate for the purposes of defining the therapeutic needs
and for evaluating the response to treatment. Like-
wise, it may not allow calibration of NIH scores of
different patients. For example, 2 patients may have
the same NIH score resulting from 2 different oral
conditions: severe-lichenoid or moderate-erythema/
ulceration. These 2 patients will need different types
of pharmacologic intervention [24,30], but the choice
of the appropriate one will be hindered by their
similar NIH score.
In line with the above, cases graded as severe-
lichenoid had a different total NIH score and NRS
for pain compared to cases graded as severe-
erythema/ulceration. This means that the total NIH
score will be indicative of the grading of severe cases.
The total NIH score was not shown to differentiate
between cases graded as being moderate-lichenoid
versus those that were moderate-erythema/ulceration.
We utilized oral pain as an indicator for the type of
oral manifestation and severity of oral cGVHD. It
should be noted that the instrument we used had
been validated for oral lichen planus rather than specif-
ically for cGVHD, which is well recognized in the
literature as being a lichen-like disease. Other correla-
tions may be needed to further evaluate the NIH scale,
such as histologic correlations of oral cGVHD
68 Biol Blood Marrow Transplant 16:62-69, 2010S. Elad et al.mucosal specimens, need for systemic drugs for
cGVHD, other target organs involved with cGVHD,
etc. It would also be logical to analyze oral cGVHD
scores vis-a`-vis the total systemic NIH cGVHD
scores.
The results of the construct validity and the inter-
nal consistency reliability analyses as well as the results
of the comparison of the stratified severity levels indi-
cate that the scoring method of the lichenoid type of
oral manifestations is the main flaw of the NIH scale.
Too much weight is given to lichenoid type of oral
manifestations in the overall score. This does not,
however, lessen the importance of lichenoid changes
in the diagnosis of oral cGVHD.
The scale does not specify how the overall severity
level should be scored. Rather, it is applied as 4 inde-
pendent severity scales, 1 for each type of oral manifes-
tation. A single overall severity score would ease
communication between clinicians and would also
reflect the relation between severities of different
oral manifestations.
Our results taken together suggest that redefini-
tion of the severe-lichenoid level may improve the
quantitative accuracy of the NIH scale. It was reported
in the literature that very few if any cGVHD patients
would be scored as ‘‘severe’’ because the ulcerations
rarely exceed 20% of the total mucosal surface areas
evaluated [11]. Therefore, to achieve a relative score
for these few severe ulcerative cGVHD cases and the
most severe cases of lichenoid cGVHD, the NIH
scale’s threshold for the severe lichenoid type cGVHD
should be raised (ie, higher than 50% of mucosal sur-
face involvement). Such an adjustment will probably
improve the construct validity and the internal consis-
tency reliability as well as the scale’s ability to differen-
tiate cGVHDpatients according to their severity level.
Previously suggested scales in the literature endorse
a similar concept in which the lichenoid score has
a lower weight in the overall score [9,17].
In summary, the 2005 NIH scale advances stan-
dards of cGVHD management and therapeutic trials,
and is an essential aid in accelerating development of
novel therapeutic agents in cGVHD. To the best of
our knowledge, this is the first study to validate the
NIH scale for application to oral cGVHD. Since its
publication, we have used it routinely and found that
the basic configuration of the scale is suitable, and
that it allows quantitative measures in our clinical
setting. Our current study results show that the scale
correlates with the numerical total score. In addition,
the NIH scale showed good internal consistency reli-
ability in regard to part of its components. However,
the scale’s ability to differentiate cGVHD patients
according to their severity level needs further adjust-
ment. This partial differentiation may hinder the
scale’s ability to reflect the patient’s response to
treatment.SUPPLEMENT
Prestudy statistical analysis was performed to
confirm that the analysis per evaluation (n5 75) will
have a trend similar to an analysis per patient (n5 20).
The construct validity (Pearson’s correlation) and
internal consistency reliability (Pearson’s correlation
and Cronbach’s alpha test) were calculated for the
data collected during first evaluation for each patient
(n5 20).
The results of this statistical analysis of the data per
patient demonstrated a trend similar to the statistical
analysis of the data per evaluation (see Results section
and Table 2 for the detailed information on the analy-
sis per evaluation). The Cronbach’s alpha for the
evaluation per patient was 0.696. The values of the
Pearson’s correlation for the analysis per patient are
not presented for purposes of brevity (data available
on request).
Therefore, it appears that analysis per evaluation
will be reliable for reflecting the entire study. It is
worth mentioning that there was an interval of at least
3 weeks between evaluations per patient, with a regular
interval of 3 months. This assures that there had been
sufficient time for a clinical trend to have been
expressed before a patient was reevaluated.ACKNOWLEDGMENTS
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